CD63 and cancer: To show the fate of EVs originating from cancer cells in orthotopic breast cancer models, Suetsugu A. et al. obtained EVs containing CD63-GFP and showed that cancer cells secreted GFP-labelled EVs into the tumor microenvironment [80].